Glucose-dependent insulinotropic polypeptide (GIP) is a 42--amino acid incretin hormone that binds to a seven-transmembrane G-protein--coupled receptor (GIP-R) that is expressed in numerous tissues including islet β-cells and α-cells ([@B1],[@B2]). Its best-known actions in β-cells are to augment meal-related insulin secretion and over the long-term to increase proinsulin synthesis and β-cell proliferation and survival ([@B3],[@B4]). Several downstream signaling pathways from the β-cell GIP-R have been characterized. In contrast, little is known about GIP-R expression. A cAMP response element and SP1 and SP2 transcription factor binding sites are present in the 5′ promoter region, but no physiologic modulators are known ([@B4],[@B5]). As such, our understanding of GIP physiology is based solely on regulated GIP secretion and rapid metabolism to modulate its cellular actions. The one exception is the lowered number of β-cell GIP-R in animals ([@B6],[@B7]) and humans ([@B8]) with type 2 diabetes, and the resulting GIP resistance ([@B9]), which results from hyperglycemia through an unknown mechanism ([@B7],[@B10]).

Our laboratory has studied the biologic actions of PPARγ in β-cells and shown transcriptional regulation of the prodifferentiation transcription factor Pdx-1 ([@B11],[@B12]). As part of our studies, we identified the PPAR response element (PPRE) within the *pdx-1* promoter ([@B12]). We now report finding the same PPRE sequence within the rat GIP-R promoter, followed by confirming physiologic and pharmacologic regulation of GIP-R transcription in β-cells by PPARγ. Also, we provide evidence that the lowered β-cell GIP-R expression in hyperglycemic rats may result from impaired PPARγ expression.

RESEARCH DESIGN AND METHODS
===========================

Animal models.
--------------

All protocols were in accordance with the principles of laboratory animal care and were approved by the University of Vermont Institutional Animal Care and Use Committee.

60% pancreatectomy (Px) rats.
-----------------------------

The 5-week-old male Sprague-Dawley rats, and Zucker fatty (ZF, *fa/fa*) or lean controls (ZL, *fa/*+ or +/+), underwent 60% Px or sham Px as previously described ([@B11],[@B13]).

PANC PPARγ^−/−^ mice.
---------------------

Mice with PPARγ deficiency restricted to pancreatic epithelium were generated by crossing Pdx-1 Cre mice and mice with two floxed PPARγ alleles as previously detailed ([@B12],[@B14]). Controls were littermate Cre negative PPARγ floxed mice.

INS-1 cells.
------------

INS-1 (832/13) cells were cultured as previously described ([@B11],[@B12]).

Experimental methods.
---------------------

See the online appendix, available at <http://diabetes.diabetesjournals.org/cgi/content/full/db09-1655/DC1>.

Statistical analysis.
---------------------

Data are presented as mean ± SEM. Each data point from the animal studies was obtained from an individual rat or mouse. Statistical significance was determined by the unpaired Student\'s *t* test or two-way ANOVA.

RESULTS
=======

GIP-R promoter PPRE.
--------------------

We previously identified a functional PPRE in the mouse *pdx-1* promoter ([@B12]). Gene Bank blast for this nucleotide sequence found a 100% identical sequence in the rat *GIP-R* promoter at positions −871 to −883 from the transcription start site (Gene Bank: AF050667) (supplemental Fig. 1*A*, available in the online appendix). MatInspector software ([@B15]) uncovered analogous sequences in the mouse and human GIP-R promoters (supplemental Fig. 1*B*).

INS-1 cell studies.
-------------------

Studies were performed in rat-derived INS-1 cells to confirm functionality of this putative PPRE. PPARγ binding was determined with the chromatin immunoprecipitation assay. Flanking primer pairs for a 213-bp PCR product that included the GIP-R PPRE (schema in supplemental Fig. 2*A*) generated the correct-sized PCR band with input DNA and PPARγ antibody--precipitated DNA, whereas only faint bands were observed with nonimmune serum ([Fig. 1](#F1){ref-type="fig"}*A*). Representative negative and positive controls are shown in supplemental Fig. 2.

![Experiments in INS-1 cells. *A*: Chromatin immunoprecipitation assay to assess PPARγ binding to the putative PPRE on the *GIP-R* gene. Chromatin fragments (300--500 bp length) were generated. Representative gel showing chromatin preparations from two separate experiments immunoprecipitated with rabbit polyclonal anti-PPARγ (*lanes 2* and *3*) or the negative control nonimmune serum (l*anes 4* and *5*). *Lane 1* is nonimmunoprecipitated DNA. Results show the expected 213-bp PCR product with the anti-PPARγ and input DNA, but not the control serum. *B*: PPARγ siRNA. INS-1 cells underwent transfections with siRNA duplexes against the rat *PPAR*γ gene or scrambled siRNA duplexes. Cells were cultured with media that contained 10 μmol/l troglitazone or DMSO for 72 h, and the isolated RNA was assessed for GIP-R mRNA levels by RT-PCR. Representative gels show scrambled siRNA cells cultured with DMSO (*lane 1*), scrambled siRNA cells cultured with troglitazone (*lane 2*), siRNA cells cultured with troglitazone (*lane 3*), and siRNA cells cultured with DMSO (*lane 4*). Cyclophilin B mRNA was used as an internal control. *C* and *D*: Luciferase reporter transcription assay. INS-1 cells were transfected with wild-type or mutated pTAL-PPRE-rat GIP-R vectors, and 24 h post-transfection, the cells were treated with 10 μmol/l troglitazone or DMSO for 24 h. WT = wild-type rat GIP-R PPRE (CCCATG-G-AGGTCA). Mut-1 = mutation of the 5′ DR1 half-site of the rat GIP-R PPRE (AAAATA-G-AGGTCA). Mut-2 = mutation of the 3′ DR2 half-site of the rat GIP-R PPRE (CCCATG-G-ATTTTA). *C* shows the relative basal luciferase activity (DMSO-treated cells) compared with the wild-type rat GIP-R PPRE construct as means ± SEM of three separate experiments. *D* shows the troglitazone treatment effect on luciferase reporter activity of the wild-type and mutated *GIP-R* PPREs. \**P* \< 0.015 vs. DMSO-cultured wild-type *GIP-R* PPRE cells. \#*P* \< 0.001 vs. troglitazone cultured wild-type *GIP-R* PPRE cells.](zdb0061061620001){#F1}

PPARγ regulation of GIP-R expression was tested using four pooled siRNA duplexes against PPARγ in INS-1 cells that cause a 75% decrease in PPARγ protein ([@B11]). Cells were treated with troglitazone or vehicle for 72 h ([Fig. 1](#F1){ref-type="fig"}*B*). GIP-R mRNA band intensity was markedly lowered in the PPARγ siRNA cells (*lanes 1* and *4*). Troglitazone doubled it in control cells (*lane 2*), whereas the increase was eliminated when troglitazone and the PPARγ siRNA duplexes were used together (*lane 3*).

PPARγ regulation of GIP-R transcription was confirmed with a luciferase reporter gene assay that used a wild-type rat GIP-R promoter fragment and also those containing mutations in the DR1 and DR2 hexamers of the GIP-R PPRE (Mut-1 and Mut-2 fragments), subcloned into the pTAL luciferase reporter vector. The DR1 and DR2 mutations both lowered basal luciferase activity (Mut-1 63 ± 9% of wild-type GIP-R, *P* \< 0.015; Mut-2 38 ± 8% of wild-type GIP-R, *P* \< 0.002) ([Fig. 1](#F1){ref-type="fig"}*C*). Also, 24-h incubation with troglitazone ([Fig. 1](#F1){ref-type="fig"}*D*) stimulated expression of the wild-type GIP-R construct (162 ± 8% of vehicle-treated wild-type cells, *P* \< 0.002), whereas this effect was absent with both mutations.

In vivo studies.
----------------

In vivo testing of PPARγ regulation of β-cell GIP-R expression was carried out using PANC PPARγ^−/−^ mice that have a pancreas-specific deletion of PPARγ from a Cre/loxP recombinase system with Cre driven by the *pdx-1* promoter ([@B14]). We previously reported that 8-week-old male PANC PPARγ^−/−^ mice are modestly hyperglycemic, with a normal β-cell mass and normal-appearing pancreas histology and islet cytoarchitecture ([@B12]). The current studies confirmed the expected defect in GIP-R expression ([Fig. 2](#F2){ref-type="fig"}*A*, mRNA; [Fig. 2](#F2){ref-type="fig"}*B*, protein 29 ± 5% of control, *P* \< 0.0001) in isolated islets from these mice. Immunofluorescence studies of pancreas sections showed markedly lowered GIP-R staining in islet β-cells and non--β-cells of PANC PPARγ^−/−^ mice versus control mice ([Fig. 2](#F2){ref-type="fig"}*C*).

![Islet GIP-R mRNA and protein expression, and pancreas immunostaining for GIP-R, in 8-week-old male PANC PPARγ^−/−^ mice with a pancreas-specific knockout of PPARγ (KO) and littermate floxed control mice (Cre−). Representative gels showing PCR products for islet GIP-R and cyclophilin (*A*) and immunoblots for GIP-R and β-actin from two separate PANC PPARγ^−/−^ and two floxed control mice (*B*) are shown. *C*: Representative islet fields on a pancreas section from a male PANC PPARγ^−/−^ and floxed control mouse stained with rabbit GIP-R antiserum in the *left panels*, costained with insulin antiserum in the *middle panels*, and insulin antiserum alone in the *right panels*. The scale bar is 20 μm. (A high-quality digital representation of this figure is available in the online issue.)](zdb0061061620002){#F2}

Analogous studies were performed in normoglycemic Sprague-Dawley rats 14 days after 60% Px when islet nuclear PPARγ expression is 2.5-fold increased ([@B11]). Comparable increases in GIP-R mRNA ([Fig. 3](#F3){ref-type="fig"}*A*) and protein ([Fig. 3](#F3){ref-type="fig"}*B*, 1.9 ± 0.2-fold of sham, *P* \< 0.02) were found in Px versus sham rat islets. Also, GIP-R staining intensity was increased in islet β-cells and non--β-cells versus the sham rats ([Fig. 3](#F3){ref-type="fig"}*C*).

![Islet GIP-R mRNA and protein expression, and pancreas immunostaining for GIP-R, in 14-day postsurgery 60% Px and sham-operated Sprague-Dawley rats. Representative gels showing PCR products for islet GIP-R and cyclophilin (*A*) and immunoblots for GIP-R and β-actin from two separate Px and sham rats (*B*) are shown. *C*: Representative islet fields on pancreas section from a Px rat and a sham-operated rat stained with rabbit GIP-R antiserum in the left panels and costained with insulin antiserum in the right panels. The scale bar is 20 μm. (A high-quality digital representation of this figure is available in the online issue.)](zdb0061061620003){#F3}

Troglitazone studies.
---------------------

Thiazolidinedione (TZD) stimulation of GIP-R expression was tested by incubating normal mouse islets for 72 h with troglitazone or vehicle. Troglitazone caused a near-tripling of the GIP-R protein level (supplemental Figs. 3*A* and *B*, 2.7 ± 0.4-fold of DMSO islets, *P* \< 0.02). Also the insulin response to 16.7 mmol/l glucose/10 nmol/l GIP peptide was nearly doubled (*P* \< 0.05), whereas insulin responses to 2.8 mmol/l glucose with or without GIP peptide, and to high glucose alone, were unchanged (supplemental Fig. 3*C*).

Hyperglycemic rats.
-------------------

We speculated that impaired PPARγ expression caused the β-cell GIP-R depletion in animal models of type 2 diabetes ([@B6],[@B7]). Accordingly, we performed PPARγ and GIP-R Western blots on islet extracts from 3-week postsurgery 60% Px and sham-operated ZF and ZL rats, based on our report that Px ZF rats are hyperglycemic (∼15 mmol/l) with the same degree of obesity and serum levels of nonesterified fatty acids and GIP as normoglycemic sham ZF rats ([@B13]). [Figure 4](#F4){ref-type="fig"} shows that islet PPARγ and GIP-R protein levels are doubled in the sham ZF versus sham ZL rats (1.9 ± 0.1-fold, *P* \< 0.001; 2.2 ± 0.3-fold, *P* \< 0.01, respectively). In contrast, both are lowered by 60% in Px (hyperglycemic) ZF islets versus the sham (normoglycemic) ZF islets (0.7 ± 0.1-fold and 0.8 ± 0.1-fold of sham ZL islets, respectively).

![Islet GIP-R and PPARγ protein expression in Zucker fatty (*fa/fa*) and Zucker lean (*fa*/+, +/+) rats 3 weeks post 60% Px or sham-Px surgery. *A*: Representative immunoblots for GIP-R, PPARγ, and β-actin in islet extracts from 60% Px or sham-operated ZF and ZL rats. *B* and *C*: Graphs showing % means ± SEM band intensities for GIP-R and PPARγ, respectively, relative to sham-operated ZL islets using data from four separate experiments. \**P* \< 0.005 ZF sham vs. ZL sham islets. \#*P* \< 0.005 ZF sham vs. ZF Px islets.](zdb0061061620004){#F4}

DISCUSSION
==========

We used in vitro and in vivo techniques to show for the first time that GIP-R transcription in β-cells is regulated by PPARγ. Also, that pharmacologic activation of PPARγ by TZDs induces the same effect resulting in greater GIP potentiation of glucose-induced insulin secretion. These results add to our prior studies of PPARγ signaling in β-cells that showed 40% of adult mouse islet *pdx-1* expression is PPARγ regulated ([@B11],[@B12]) by our now finding a second gene with the identical PPRE and functional characteristics.

There are several noteworthy implications to these results. First, Pdx-1 is considered the most important transcription factor in β-cells related to its essential role for normal β-cell function, viability, and compensation capacity ([@B16]). Also, studies of incretin receptor knockout mice and in vivo usage of GIP-R peptide agonists have demonstrated a necessary role for GIP in normal mealtime glucose tolerance and insulin secretion ([@B17],[@B18]). Clinical trials have found a particularly high success rate of TZDs in pre-diabetes and early type 2 diabetes, with the mechanism believed to be the peripheral insulin sensitization lowering the drive for insulin secretion (so-called "β-cell rest") ([@B19]). However, given the importance of the identified PPARγ-regulated genes in β-cells, our results raise the possibility that direct PPARγ-mediated effects on β-cells also account for some of the clinical benefits. Indeed, others have shown a direct effect of TZDs to restore Pdx-1 levels and reduce endoplasmic stress in islets from diabetic rats ([@B20]).

Second, there is the possibility we have uncovered an unknown feature of incretin physiology, i.e., variable GIP-R expression, related to our finding increased islet GIP-R expression in two rat models of β-cell compensation from unrelated causes: reduced β-cell mass in 60% Px Sprague-Dawley rats ([@B21]) and mutated leptin receptors resulting in obesity, insulin resistance, and hyperlipidemia in ZF rats ([@B13]). This shared observation is particularly interesting, since there is no precedence for GIP-R hyperexpression except in the adrenocortical tumors of some individuals with Cushing\'s syndrome ([@B22]). Also, our finding that the GIP-R hyperexpression in both models was paralleled by increased β-cell expression of PPARγ ([@B11]; [Fig. 4](#F4){ref-type="fig"}) is consistent with the main conclusions of this study regarding PPARγ regulation of β-cell GIP-R expression. On the other hand, an in vitro study reported PPARα regulates β-cell GIP-R expression and speculated this effect occurs in vivo related to the β-cell fatty acid load ([@B23]). This mechanism seems unlikely in the 60% Px Sprague-Dawley rats, since serum triglyceride and free fatty acid levels are unchanged post-Px in lean rats ([@B13],[@B21]), plus islet PPARα expression is reduced ([@B13]). In contrast, ZF rats are markedly hyperlipidemic ([@B13]), making this a potential mechanism. Also the lack of a post-Px increase in PPARγ and GIP-R expression in ZL rats ([Fig. 4](#F4){ref-type="fig"}) may reflect the different times of study---3 weeks post-Px in ZL rats versus 2 weeks post-Px in Sprague-Dawley rats.

The third implication of our results is our speculation that aberrant PPARγ signaling is a new mechanism for the lowered β-cell GIP-R expression and GIP resistance in animal and human type 2 diabetes ([@B6][@B7][@B8]--[@B9]). Hyperglycemia causes this effect in animals ([@B7],[@B10]), but no mechanistic details are known except for a study that reported accelerated GIP-R degradation in islets cultured at high glucose conditions ([@B24]). [Figure 4](#F4){ref-type="fig"} supports our proposal by showing parallel reductions in islet expression of PPARγ and GIP-R in the hyperglycemic ZF rats. However, Px ZF rats also have a reduction in islet PPARα mRNA expression ([@B13]), so the exact mechanism is unknown. A related issue is the lowered β-cell expression for the other incretin hormone receptor (GLP-1) in animals and humans with type 2 diabetes ([@B7],[@B8]). However, the molecular mechanism is likely different from the GIP-R depletion based on the study by Xu et al. ([@B7]) that performed 96-h glucose infusions in conscious rats and found islet GLP-1R mRNA levels fell 50%, whereas GIP-R mRNA levels modestly increased, plus they noted the same divergence in 2-day high glucose cultured islets. Also, it is likely that the lowered islet incretin receptor expression in type 2 diabetes is multifactorial, with recent interest in disrupted TCF7L2 signaling ([@B8]). Thus, our results suggest that β-cell PPARγ regulation of GIP-R expression is a newly identified feature of incretin (patho)-physiology and TZD therapeutics. Also the lowered islet PPARγ expression in Px ZF rats (glycemia 15 mmol/l) may provide a new understanding why TZD therapy is so powerful in pre-diabetes and early type 2 diabetes as opposed to the more modest efficacy with advanced type 2 diabetes ([@B19],[@B25]).

In summary, GIP-R is a newly described PPARγ-regulated gene in β-cells. Expression of both genes is increased in rat models with β-cell adaptation to diverse stimuli. Also, TZDs augment GIP potentiation of glucose-induced insulin secretion through this mechanism. In contrast, this expression system is downregulated in diabetic rats. As such, our studies have uncovered a new mechanism for regulatory control of the β-cell GIP-R expression and may have added a new understanding to incretin (patho)-physiology and TZD therapy.
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